NASDAQ:RKLB • US7731211089
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ROCKET LAB CORP (RKLB).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-19 | Clear Street | Initiate | Buy |
| 2026-03-13 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2026-02-27 | Citizens | Reiterate | Market Perform -> Market Perform |
| 2026-02-27 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2026-01-20 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2026-01-20 | B of A Securities | Maintains | Buy -> Buy |
| 2026-01-16 | Morgan Stanley | Upgrade | Equal-Weight -> Overweight |
| 2026-01-15 | Keybanc | Downgrade | Overweight -> Sector Weight |
| 2025-12-23 | Needham | Maintains | Buy -> Buy |
| 2025-12-22 | Stifel | Maintains | Buy -> Buy |
| 2025-11-25 | Needham | Reiterate | Buy -> Buy |
| 2025-11-19 | B of A Securities | Maintains | Buy -> Buy |
| 2025-11-12 | Needham | Maintains | Buy -> Buy |
| 2025-11-12 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-11-11 | Stifel | Reiterate | Buy -> Buy |
| 2025-10-17 | Keybanc | Maintains | Overweight -> Overweight |
| 2025-10-16 | Baird | Initiate | Outperform |
| 2025-10-13 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-09-03 | Needham | Reiterate | Buy -> Buy |
| 2025-08-08 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2025-08-08 | Needham | Maintains | Buy -> Buy |
| 2025-08-08 | Keybanc | Maintains | Overweight -> Overweight |
| 2025-08-05 | Stifel | Maintains | Buy -> Buy |
| 2025-07-16 | B of A Securities | Maintains | Buy -> Buy |
| 2025-07-14 | Citigroup | Maintains | Buy -> Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 244.592M 15.92% | 436.214M 78.34% | 601.799M 37.96% | 904.78M 50.35% | 1.261B 39.37% | 1.532B 21.49% | 1.946B 27.02% | 2.576B 32.37% | 3.774B 46.51% | 5.004B 32.59% | 6.249B 24.88% | |
| EBITDA YoY % growth | -148.174M -41.59% | -156.146M -5.38% | -184.903M -18.42% | -9.847M 94.67% | 164.47M 1,770.19% | 323.48M 96.68% | 510.51M 57.82% | 807.84M 58.24% | 1.027B 27.13% | N/A | N/A | |
| EBIT YoY % growth | -177.918M -32.18% | -189.801M -6.68% | -228.838M -20.57% | -121.214M 47.03% | 55.937M 146.15% | 195.62M 249.71% | 326.4M 66.85% | 835.58M 156.00% | 1.243B 48.76% | 1.684B 35.48% | N/A | |
| Operating Margin | -72.74% | -43.51% | -38.03% | -13.40% | 4.44% | 12.77% | 16.77% | 32.44% | 32.94% | 33.65% | N/A | |
| EPS YoY % growth | -0.38 -52.00% | -0.37 2.63% | -0.37 | -0.21 42.89% | 0.08 138.62% | 0.27 234.38% | N/A | N/A | N/A | N/A | N/A |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.08 37.18% | -0.05 61.38% | -0.06 -101.08% | -0.04 55.23% | 0.02 121.65% | 0.03 160.95% | 0.04 160.87% | 0.04 193.67% |
| Revenue Q2Q % growth | 194.63M 58.79% | 206.16M 42.67% | 229.08M 47.72% | 282.03M 56.99% | 259.15M 33.15% | 304.23M 47.57% | 327.75M 43.07% | 334.2M 18.50% |
| EBITDA Q2Q % growth | -24.249M 51.96% | -10.606M 74.85% | 4.279M 114.37% | 18.069M 354.24% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -49.427M 16.49% | -39.983M 32.96% | -26.646M 54.81% | -18.997M 62.78% | 11.903M 124.08% | 22.597M 156.52% | 27.222M 202.16% | 27.775M 246.21% |
All data in USD
23 analysts have analysed RKLB and the average price target is 85.59 USD. This implies a price increase of 27.3% is expected in the next year compared to the current price of 67.23.
The consensus EPS estimate for the next earnings of ROCKET LAB CORP (RKLB) is -0.08 USD and the consensus revenue estimate is 194.63M USD.
The number of analysts covering ROCKET LAB CORP (RKLB) is 23.